The specific objectives of the Pathology and Tissue Procurement Core are to: Provide a centralized resource dedicated to procurement and processing of tumor tissue for translational research from nearly every patient with newly diagnosed or relapsed primary central nervous system tumors receiving care at the Mayo Clinic, Rochester, MN. - Coordinate acquisition and timely distribution of brain tumor tissue in excess of clinical diagnosis, ensuring appropriate diagnosis and quality of tissue. A portion of fresh tumoral brain tissue and normal tissue (when available) from each patient will be obtained fresh, processed for culture/xenografting and/or stored frozen to provide investigators with DNA and RNA. The remainder of the tissue will be available in paraffin blocks stored at the Mayo Clinic Tissue Registry. Provide a comprehensive histologic characterization of all tissue samples used in the individual SPORE Projects, including specimens from patients and experimental tumors in animals, as well as provide expertise in the interpretation of studies performed on paraffin embedded and/or frozen tissue sections. - Offer comprehensive services, including immunohistochemical characterization of biomarkers, tissue microarray design and construction, and DNA or RNA extraction. - Maintain and enhance a repository of tumor tissue and matched blood specimens in conjunction with the Clinical Research Core. The Core will interface with and be electronically integrated with the Clinical Research and the Biostatistics Cores to provide investigators with clinically annotated tissues. The collection, banking, and use of tissue will be performed with appropriate patient consent and institutional approval. - Promote and facilitate sharing of tissue resources with other Brain Tumor SPOREs through collaborative scientific projects of mutual interest.

Public Health Relevance

Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility and adaptive skills. Well characterized, pathologically and clinically annotated tumor tissues from patients with malignant gliomas are a critical and precious resource on translating the basic molecular and biological understanding of gliomas into improved treatments for patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-09
Application #
8729258
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$90,579
Indirect Cost
$32,658
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13

Showing the most recent 10 out of 254 publications